2020 to 2021 and Beyond.: The Strength, Vision and Resilience of Workforces

2020 Annual Demographic Survey of Parkinson’s Disease and Movement Disorder Nurse Specialists

<abstract xmlns="http://www.w3.org/1999/xhtml"><bold>Introduction:</bold> We describe an Australian experience of infusional bevacizumab for vestibular schwannoma (VS) in neurofibromatosis type 2 patients, with specific focus on 3-dimensional tumour volume and audiometry.<bold>Method:</bold> Data was pooled from patients with symptomatic or progressive VS from 2009 to April 2018. Tumours were assessed as total volume per patient. Bevacizumab infusions were administered every 2-4 weeks. 3-D volumetric response (cm3) was determined through serial magnetic resonance imaging, at baseline and at 3-6-month intervals, until cessation of infusions following progression or prior to surgery. Volumetric response was defined as a reduction of volume ³ 20%, from baseline. Patients underwent interval pure tone audiometry. A decrease in the average pure tone analyses by 10dB indicated response.<bold>Results:</bold> Twenty-one VS tumours were identified in eleven patients. Median age was 26 (range 13 – 67yr). Average baseline tumour volume was 14.17cm3 (range 1.45cm3 - 38.51cm3). Tumour volume reduction >20% was shown in 7/11 patients (64%), indicating partial response, 2/11 (18%) patients showed stable disease, and 2/11 (18%) progressed. Average percentage tumour volume change was +4.45% from baseline (range -57% to 241%). 16 individual ears were tested, 3/16 (19%) of ears showed an average decibel reduction of 10dB or more, indicating response (average change 2.5dB, range -36dB to 81dB). 10/16 (63%) showed stable hearing, and 3/16 (19%) showed hearing deterioration.<bold>Conclusion:</bold> Bevacizumab is a useful agent for reducing tumour volume and improving hearing losses due to vestibular schwannoma in neurofibromatosis type 2 patients. These results reflect results described from the United Kingdom and United States.</abstract>

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

<abstract xmlns="http://www.w3.org/1999/xhtml">Parkinson’s disease is the second most common neurological disorder after dementia in Australia (<xref ref-type="bibr" rid="j_ajon-2021-003_ref_003">Deloitte, 2015</xref>). The complexities of caring for a person with Parkinson’s disease highlights the need for Parkinson’s disease and movement disorder nurse specialists (PDMDNS) (<xref ref-type="bibr" rid="j_ajon-2021-003_ref_002">Bramble, Carroll, &amp; Rossiter, 2018</xref>).The Australasian Neuroscience Nurses Association’s (ANNA) Movement Disorder Chapter (MDC) aims to implement an annual demographic survey over the next 10 years to capture the characteristics of the PDMDNS cohort, identify gaps in service provision and aid the workforce planning through useful and influential data.The results of this survey were able to highlight the geographical areas that are underserviced, the diverse employment opportunities available and the issues around financial funding for PDMDNS positions in Australia.</abstract>

AHEAD OF PRINT

Volume 34 (2024): Issue 1 (May 2024)

Volume 33 (2023): Issue 2 (October 2023)

Volume 33 (2023): Issue 1 (May 2023)

Volume 32 (2022): Issue 2 (October 2022)

Volume 32 (2022): Issue 1 (May 2022)

Volume 31 (2021): Issue 2 (October 2021)

Volume 31 (2021): Issue 1 (May 2021)

Volume 30 (2020): Issue 2 (October 2020)

Volume 30 (2020): Issue 1 (May 2020)

Volume 29 (2019): Issue 2 (May 2019)

Volume 29 (2019): Issue 1 (May 2019)

Volume 28 (2018): Issue 2 (November 2018)

Volume 28 (2018): Issue 1 (June 2018)

Volume 27 (2017): Issue 2 (November 2017)

Volume 27 (2017): Issue 1 (November 2017)

Volume 26 (2016): Issue 2 (May 2016)

Volume 26 (2016): Issue 1 (May 2016)

Volume 25 (2015): Issue 2 (October 2015)

Volume 25 (2015): Issue 1 (May 2015)

Australasian Journal of Neuroscience

Australasian Journal of Neuroscience (AJoN) Journal Scope and Aims  Published bi-annually (May and October), the Australasian Journal of Neuroscience (AJoN), the official journal of the Australasian Neuroscience Nurses Association (ANNA), has published original peer reviewed articles since 1988 making it one of the longest standing neuroscience nursing journals.  The AJoN is an international peer reviewed open access journal that aims to promote the development and exchange of knowledge that reflects the broad and emerging interests of neuroscience nursing and the neuroscience nursing profession. The AJoN is at the forefront of disseminating and communicating knowledge and through the promotion of clinically related scholarship, the AJoN supports and advances the practice and discipline of neuroscience nursing.  The mission of the AJoN is to further the neuroscience nursing profession through representation and the provision of works that best represent neuroscience nursing expertise and experience. Through this provision evidence is translated into neuroscience nursing practice to improve health outcomes for individuals, families, and populations.  Fields of nursing represented in the AJoN include, but are not limited to, neurology, movement disorders, neurosurgical, neuro-intensive, neuro-rehabilitative, neuropsychiatry, neuro-gerontology, neuro-paediatric, neuro-emergency and neuro-trauma. Contributions are also welcome from other healthcare fields on issues and developments that have a direct impact on neuroscience nursing practice.  The AJoN welcomes manuscripts from both new and experienced authors wishing to contribute neuroscience knowledge to nursing practice and research. Both National and International submissions are welcome, with the AJoN supporting the exchange of ideas and experience that represents different practices and cultures.  Submitted original articles should make a novel contribution to neuroscience nursing with examples including advances in neurosurgical and neurological nursing, patient care, complex care interventions, research, policy, professional issues, and theory. Submissions must be of a high quality and the journal accepts various article types including (but not limited to) review articles, systematic reports, case series, case studies, quantitative, qualitative, and mixed methods research articles, practice updates, guest editorials, clinical trials, quality improvement articles, letters to the editor, commentaries, and the development of new guidelines that provide a unique insight into the field of neuroscience nursing. The journal’s purpose is to advance the field of neuroscience nursing by presenting published works with an emphasis on knowledge that will influence the way neuroscience nursing is practiced, taught, researched, and administrated. This information is applicable to nurses working in clinical, administrative, educational,  leadership and research settings. Each issues contains a variety of papers, commentaries and published works resulting from the National ANNA conference. The target audience of the AJoN includes nurses, student nurses, nurse practitioners, managers, executives, administrators, educators, and higher research degree students as well as allied health professionals.  Topics relevant to the AJoN include the development of clinical research and knowledge, evidenced based practice, leadership, and scientific enquiry. Works that explore the patient and family experience, illness, and recovery within the neuroscience field. Organisational factors including governance, patient safety, role development and models of service delivery. As well as cultural comparisons and evaluations of neuroscience nursing practice across different healthcare sectors, social and geographical settings.  The AJoN offers authors the benefits of a highly respected journal in the field of neuroscience nursing, indexed in a wide range of databases including (EBSCO, Elsevier, MIAR, MtScienceWork, ReadCube, SCILIT and Semantic Scholar). The journal has a truly global readership, rapid manuscript screening and efficient editorial processes. The journal also offers a highly visual format, with full colour figures, images, and tables.  The AJoN Editor is advised and supported by a Board of Reviewers that represent all facets of neuroscience nursing. Submitted papers are reviewed by Reviewers who meet a high standard of academic and clinical expertise. The AJoN will ensure that practice and policy development is evidenced based, research is informed at an advanced level and that readers are challenged to engage in critical debate and critically reflect on the interface between practice, policy, and research. The AJoN team believes that every neuroscience nurse should have the opportunity to grow and develop their practice and career through quality education and professional development. The AJoN is essential reading for anyone with an interest in neuroscience nursing.   Archiving  Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.  Plagiarism Policy  The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 

Australasian Journal of Neuroscience

Volume 31 (2021): Issue 1 (May 2021)

2020 to 2021 and Beyond.: The Strength, Vision and Resilience of Workforces

2020 Annual Demographic Survey of Parkinson’s Disease and Movement Disorder Nurse Specialists

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

2020 Annual Demographic Survey of Parkinson’s Disease and Movement Disorder Nurse Specialists

Cerca

Tutti i volumi ed i numeri in questa rivista